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Evidence-Based Smoking Cessation 
Treatment for Disparate Populations 
 
Chizimuzo Okoli, PhD, MPH, RN 
Assistant Professor and Director, 
Tobacco Treatment and Prevention Division, 
Tobacco Policy Research Program, 
University of Kentucky College of Nursing 
Overview 
• Describe Research Group and Program of Research 
among disparate Populations 
 
• Discuss smoking among persons with substance use 
and mental illness 
 
• Present smoking cessation outcomes from evidence-
based programs for persons with substance use 
disorders and mental Illness 
 
• Conclusion with current and future Projects 
RESEARCH GROUP 
 AND PROGRAM OF RESEARCH 
Clean Indoor Air Partnership 
Air Quality 
Monitoring  
Tobacco Policy 
Research  Program 
Kentucky Center for 
Smoke-Free Policy 
Rural Smoke-Free 
Communities Project 
Tobacco Treatment 
and Prevention 
Program 
Freedom from Radon 
Exposure and 
Smoking in the Home 
(FRESH) 
Radon Policy 
Research Program 
Secondhand Smoke  
& 
Smoking Behaviours 
 
Developing Tailored 
tobacco treatment for 
individuals with 
mental illness 
Smoking cessation 
program within 
outpatient Psychiatric 
Services  
(BREATHE UK) 
Smoking cessation 
program  
for  
Homeless persons  
(HOPE Center) 
Tobacco 
Treatment and 
Prevention 
Division 
Tobacco Treatment  
within  
Outpatient Services in 
Hospitals 
(VGH SCC) 
Program of Research 
Tobacco Treatment In 
for people with 
Mental illness 
(Participation Station) 
SMOKING AMONG PERSONS WITH  
SUBSTANCE USE AND MENTAL 
ILLNESS 
Background and Significance 
• “Nicotine-dependent 
individuals with a 
comorbid psychiatric 
disorder made up 7.1% 
of the population yet 
consumed 34.2% of all 
cigarettes smoked in the 
United States” 
 
 
 
 
Grant, B.F. , Hasin, D.S., Chou, S.P., Stinson, F.S.& Dawson, D.A. (2004). Nicotine dependence and psychiatric disorders in the United States: Results from a 
national epidemiologic survey on alcohol and related conditions. Archives of General Psychiatry,61,1107-1115. 
Past Month Cigarette Use among Adults Aged 18 or Older, by Any Mental Illness in 
the Past Year and Gender, by Age Group: 2009 to 2011 
 Kalman, Morissette and George (2005), Am. J. Addict., 14: 106-123  
Health effects of smoking among 
persons with mental illness 
Nonsmokers with Mental 
illness : 
• Have better health 
• Live longer 
• Need less medication 
• Have less depression 
• Save more money 
 
 
 
 
 Smokers with Mental illness : 
• Die 10 years earlier 
• Have more depression 
and depression 
• Have more substance 
use problems 
• Have more chest and 
heart problems 
• Are more likely to commit 
suicide 
• Have sexual problmes 
 
 
 
Reasons for smoking among individuals with 
substance use disorders and mental illness 
 
 
• Psychosocial 
• Genetic • Bio-behavioral 
Smoking and substance use: Genetic 
• Both common and specific addictive factors for alcohol, marijuana, 
cocaine, and habitual smoking transmitted in families 
 
• This specificity suggested independent causative factors for the 
development of each substance dependence 
 
• 68% of the association between nicotine and alcohol dependence 
explained by shared genetic effects. 
 
Bierut LJ, Dinwiddie SH, Begleiter H, et al. Familial Transmission of Substance Dependence: Alcohol, Marijuana, Cocaine, and Habitual Smoking: A Report From the Collaborative 
Study on the Genetics of Alcoholism. Archives of General Psychiatry 1998; 55:982-988 
True WR, Xian H, Scherrer JF, et al. Common Genetic Vulnerability for Nicotine and Alcohol Dependence in Men. Archives of General Psychiatry 1999; 56:655-661 
Smoking and mental illness: Genetic 
 
(8,169 male twins) shared genetic disorders further predispose 
to major depression and nicotine dependence.  
 
Kendler KS, Neale MC, MacLean CJ, et al. Smoking and Major Depression: A Causal Analysis. Archives of General Psychiatry 1993; 50:36-43 
Lyons M, Hitsman B, Xian H, et al. A twin study of smoking, nicotine dependence, and major depression in men. Nicotine & Tobacco Research 
2008; 10:97 - 108 
(1,566 female twin pairs) average life time daily cigarette 
consumption was found to be associated with life time 
prevalence of major depression, suggesting that the 
relationship between smoking and major depression 
resulted solely from genes which predispose to both 
conditions. 
• 63% of the association between post traumatic stress disorder 
and nicotine dependence co-morbidity explained by shared 
genetic effects. 
Koenen KC, Hitsman B, Lyons MJ, et al. A Twin Registry Study of the Relationship Between Posttraumatic Stress Disorder and Nicotine Dependence in Men. Archives of 
General Psychiatry 2005; 62:1258-1265 
Faraone et al. (2004). A novel permutation testing method implicates sixteen nicotinic acetylcholine receptor genes as risk factors for smoking in Schizophrenia families 
Smoking and mental illness: Genetic   
• A group of candidate genes and individual genes found 
among individuals with schizophrenia significantly linked to 
smoking behaviors. 
Smoking and substance use: Bio-behavioral 
Marijuana use reduces cessation of tobacco smoking in adults 
Ford, Vu, Anthony. (2002) Drug and Alcohol Dependence; 67:243-248 
 
 
 
Nicotine increases alcohol self-administration in non-
dependent male smokers.  
Barrett,Tichauer, Leyton, et al. (2006). Drug and Alcohol Dependence; 81:197-204 
 
 
 
 
Increases in methadone dose could increase nicotine craving 
and cigarette consumption for individuals with opioid-
dependence  
Story & Stark. (1991). Journal of psychoactive drugs, 23:203-215 
 
 
Cigarette smoking primes the brain to cocaine use 
Levine et al. (2011). Science translational medicine, 3, 107, 107-109  
 
 
 
 
 
 
 
Smoking and mental illness: Bio-behavioral 
 
 
 
 
 
 
Nicotine reduces sensorimotor gating deficits in smokers with 
schizophrenia 
Postma et al. (2006). Psychopharmacology, 184: 589–599 
 
 
 
 
 
Brain levels of monoamine oxidase A (MAO-A) (an enzyme 
associated with depression) were reduced in smokers relative 
to nonsmokers; suggesting that people with affective 
disorders may smoke to reduce elevated MAO-A levels in the 
brain 
Fowler, Volkow, Wang, et al. (1996). Proceedings of the National Academy of Sciences of the United States of America, 93:14065-14069 
 
Smokers with a primary diagnosis of anxiety disorder 
reported greater levels of general anxiety, distress, and 
depression as compared to nonsmokers. 
McCabe, Chudzik, Antony, et al. (2004). Journal of Anxiety Disorders, 18:7-18 
Substance use and Smoking: Psychosocial 
Glautier S, Clements K, White JAW, et al. Alcohol and the reward value of cigarette smoking. Behavioural Pharmacology 1996; 7:144-154 
King AC, Epstein AM. Alcohol Dose-Dependent Increases in Smoking Urge in Light Smokers. Alcoholism: Clinical & Experimental Research 2005; 29:547-552 
Friend KB, Pagano ME. Smoking initiation among nonsmokers during and following treatment for alcohol u se disorders. Journal of Substance Abuse Treatment 2004; 26:219-224 
Bobo JK, Husten C. Sociocultural Influences on Smoking and Drinking. Alcohol Research & Health 2000; 24:225-232 
Crum RM, Lillie-Blanton M, Anthony JC. Neighborhood environment and opportunity to use cocaine and other drugs in late childhood and early adolescence. Drug and Alcohol 
Dependence 1996; 43:155-161 
Wagner FA, Anthony JC. Into the world of illegal drug use: Exposure opportunity and other mechanisms linking the use of alcohol, tobacco, marijuana, and cocaine. Am. J. Epidemiol. 
2002; 155:918-925 
• Tobacco use may foster the use of other substances; and 
vice versa 
• Drug treatment centers may provide an environment 
that supports tobacco use or a factor for delayed 
tobacco use cessation. 
• Factors such as neighborhood disadvantage and early 
exposure to substance use may present an ‘exposure 
opportunity’ for subsequent substance use.  
Smoking mental illness: Psychosocial 
• History of tobacco use as a token economy--
cigarettes used as a ‘reward’ for appropriate 
behavior (i.e., smoking privileges) 
 
 
 
 
• Smoking among clients and staff to encourage 
‘socialization’  
 
Kawachi I, Berkman L. Social ties and mental health. Journal of Urban Health 2001; 78:458-467 
Lawn S. Cigarette smoking in psychiatric settings: occupational health, safety, welfare and legal concerns. Australian and New Zealand Journal of Psychiatry 2005; 39:886-891 
Keizer I, Eytan A. Variations in Smoking during Hospitalization in Psychiatric In-Patient Units and Smoking Prevalence in Patients and Health-Care Staff. International Journal of Social 
Psychiatry 2005; 51:317-328 
Morisano D, Bacher I, Audrain-McGovern J, et al. Mechanisms underlying the comorbidity of tobacco use in mental health and addictive disorders. Canadian Journal Of Psychiatry. Revue 
Canadienne De Psychiatrie 2009; 54:356-367 
Arguments for Not Providing Tobacco Treatment…. 
“these patients don’t want to quit” 
• However….80% of participants in a methadone maintenance 
program and 75% of participants in an alcohol abuse 
program endorsed a desire to quit  
(Richter KP et al., 2001; Ellingstad TP et al, 1999)  
 
 
 
• In a review of 9 studies of motivation to quit smoking among 
individuals with psychiatric disorders at least 50% are 
contemplating cessation  
(Siru, Hulse & Tait, 2009).  
“these patients will relapse (to other substances) if 
they try to quit” 
 
• Smoking cessation related to IMPROVED QUALITY OF LIFE 
 
 
 
 
 
• Meta-analysis (n = 19 studies) of smoking cessation among 
individuals in addiction treatment and recovery found that 
smoking cessation efforts can ENHANCE rather than 
compromise long-term sobriety  
 
 
 
 
 
 
 
 
 
 
Bobo JK, McIlvain HE, Lando HA, et al. Effect of smoking cessation counseling on recovery from alcoholism: findings from a randomized community intervention trial. Addiction 1998; 93:877-
887 
McCarthy WJ, Zhou Y, Hser YI, et al. To smoke or not to smoke: Impact on disability, quality of life, and illicit drug use in baseline polydrug users. Journal of Addictive Diseases 2002; 21:35-54 
Lemon SC, Friedmann PD, Stein MD. The impact of smoking cessation on drug abuse treatment outcome. Addictive Behaviors 2003; 28:1323-1331 
Mc Carthy WJ, Collins C, Hser YI. Does cigarette smoking affect drug abuse treatment? Journal of Drug Issues 2002; 2:61-80 
Prochaska JJ, Delucchi K, Hall SM. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. Journal of Consulting and Clinical 
Psychology 2004; 72:1144-1156 
“these patients are unable to quit” 
• Meta-analysis (n = 19 studies) of smoking cessation among 
individuals in addiction treatment and recovery found increased 
cessation at end of 12 weeks treatment 
     (Prochaska JJ et al, 2004). 
 
 
• Another recent study found end-of-treatment (between 8 to 26 
weeks) smoking cessation rates of 40% among individuals with 
SUD and/or PD who completed an intensive tailored smoking 
cessation intervention that provided no-cost pharmacotherapy 
combined with behavioural counseling 
         (Khara and Okoli, 2011) 
           
 
• Concerns that smoking cessation will increase 
psychiatric symptoms or relapse among patients.  
o Among individuals with depression, smoking cessation related to 
increased depression symptomatology, which is one of the 
symptoms of the nicotine withdrawal syndrome 
o individuals with anxiety disorders and depression report more 
severe withdrawal symptoms 
o smoking is associated with improvements in prepulse inhibition 
and sensory gating which may be affected by smoking cessation 
 
• Smoke-free policy and mental health facilities 
o a review of studies examining prohibitions of smoking in 
psychiatric facilities suggests that prohibitions do not have long-
term effects on behavioral unrest or noncompliance, but neither 
do they appear to effect smoking cessation 
Patten C, Martin J. Does nicotine withdrawal affect smoking cessation? Clinical and theoretical issues. Annals of Behavioral Medicine 1996; 18:190-200 
Breslau N, Kilbey MM, Andreski P. Nicotine withdrawal symptoms and psychiatric disorders: findings from an epidemiologic study of young adults. American Journal of Psychiatry 1992; 
149:464-469 
Adams CE, Stevens KE. Evidence for a role of nicotinic acetylcholine receptors in schizophrenia. Frontiers in Bioscience 2007; 12:4755-4772 
Kumari V, Postma P. Nicotine use in schizophrenia: The self medication hypotheses. Neuroscience & Biobehavioral Reviews 2005; 29:1021-1034 
el-Guebaly N, Cathcart J, Currie S, et al. Public health and therapeutic aspects of smoking bans in mental health and addiction settings. Psychiatr Serv 2002; 53:1617-1622 
Ziedonis DMa, Williams JMb. Management of smoking in people with psychiatric disorders. Current Opinion in Psychiatry 2003; 16:305-315 
Barriers to facilitating tobacco treatment 
Costs associated with smoking cessation treatment 
• Even though less expensive than purchasing cigarettes, 
the cost of pharmacotherapy and counseling presents 
an important barrier to seeking treatment 
 
• Such cost barriers to accessing treatment and the 
potential cost-effectiveness of treatment have 
prompted guidelines about reducing medication costs 
(reduced cost or free of charge), inclusion of 
medications as benefits on drug insurance plans, and 
setting up systems for reimbursement for tobacco 
cessation treatment for health care providers. 
Bansal MA, Cummings KM, Hyland A, et al. Stop-smoking medications: Who uses them, who misuses them, and who is misinformed about them? Nicotine & Tobacco Research 2004; 6:303-
310 
Reilly P, Murphy L, Alderton D. Challenging the smoking culture within a mental health service supportively. International Journal of Mental Health Nursing 2006; 15:272-278 
Fiore M, Jaén C, Baker T, et al. A Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 Update: A U.S. Public Health Service Report. American Journal of Preventive 
Medicine 2008; 35:158-176 
Raw M, McNeill A, West R. Smoking cessation: evidence based recommendations for the healthcare system. British Medical Journal 1999; 318:182-185 
Smoking Cessation Outcomes of evidence-based 
program for individuals with Substance Use 
Disorders and Mental Illness 
          
• The Tobacco Dependence Clinic (TDC) for 
individuals with primarily substance use 
disorders and addictions 
 
• The Butt-Out Group (Butt-Out) for individuals 
with primarily mental illnesses 
Program Overview 
• 24-26 weeks  
o TDC (8 weeks structured, up to 18 weeks of support) 
o Butt Out group (12 weeks structured, up to 12 weeks support) 
 
• Tailored pharmacotherapy for up to 26 weeks at no cost 
 
• Program is run with a team of nurses, counsellors, 
respiratory therapists, Occupational therapists, and a 
physician 
 
 
TREATMENT PHILOSOPHY 
Smoking cessation is a ‘process’ not an event. Hence the program has no 
specific ‘quit date’. Also the program employs the concept of ‘titration-to-
effect’ in which increasing doses of nicotine replacement therapy is 
provided until the behavior of smoking ceases.   
Criteria 
Eligibility: 
• 19 years or older 
• Tobacco dependent 
• Have a history of substance use disorder (SUD) and/or 
psychiatric disorder (PD) 
• Financially disadvantaged 
 
Assessment: 
• 1 hour evaluation of medical, psychiatric, substance 
and tobacco use history 
• Expired air CO is determined and a treatment plan is 
developed in consultation with client 
Phases of Treatment  
Tailored 
 Pharmacotherapy 
8
 -
1
2
 W
e
e
k
s
 
U
p
 t
o
 2
4
- 
2
8
 
W
e
e
k
s
 Tailored 
 Pharmacotherapy 
Behavioral Counseling  
 
Support Group 
Tailored 
 Pharmacotherapy 
Behavioural Counseling (Weeks 1-8) 
• Phase 1: engagement in the process – weeks 1-2 
 
• Phase 2: planning for change – weeks 3-4 
 
• Phase 3: sustaining change – weeks 5-8 
Combination Pharmacotherapy 
Nicotine Replacement Therapy 
 
 
 
Oral Medications  
 
 
 
Patch 
Gum 
Lozenge 
Inhaler 
Zyban 
Champix 
Gender 
0 
20 
40 
60 
80 
100 
39.1 
60.9 
Female 
Male 
TDC (N =647) 
0
20
40
60
80
100
43.4
56.6
Female
Male
Butt Out Group (N = 76) 
Substance Use Disorder History (either past or current use) 
0.0
20.0
40.0
60.0
80.0
100.0
11.0
35.9
8.8
25.5
14.5
4.3
0.0 
20.0 
40.0 
60.0 
80.0 
100.0 
47.4 
13.2 
1.3 
5.3 
30.3 
2.6 P
e
rc
e
n
t 
%
 
TDC (N = 647) Butt Out Group (N = 76) 
P
e
rc
e
n
t 
%
 
Psychiatric Disorder History  (either past or current, N =  647) 
56.6%
6.5%
15.1%
21.8%
Mood (n = 266)
Psychotic (n = 42)
Anxiety (n = 98)
None (n = 141)
TDC (N =647) 
Butt Out Group (N = 76) 
71.8
26.8
Mood (n = 51)
Psychotic (n = 20)
Co-occurring Disorders history  
(either past or current) 
0 
20 
40 
60 
80 
100 
3.6% 7.4% 
18.2% 
70.8% 
0
20
40
60
80
100
43.7% 56.3%
Psych only
Concurrent
TDC (N = 647) 
Butt Out Group (N = 76) 
Sample Characteristics 
TDC (N = 647) 
Mean (SD) 
Butt-Out (N =76) 
Mean (SD) 
Age of participant (years) 
 
47.3 (11.4) 47.2 (10.6) 
Age at smoking initiation (years) 
 
14.7 (4.9) 18.1 (6.4) 
Importance of quitting (scale of 0 ‘low’ to 10 ‘high’) 9.0 (1.3) 9.0 (1.6) 
Confidence in quitting (scale of 0 ‘low’ to 10 ‘high’) 
 
7.3 (2.2) 6.9 (2.3) 
Number of cigarettes smoked per day 
 
20.9 (10.5) 22.5 (10.5) 
Fagerstrom Test for Nicotine Dependence  
(scale of 0 ‘low’ to 10 ‘high’) 
 
6.1 (2.1) 6.1 (2.0) 
CO level at baseline (ppm) 20.5 (12.6) 22.8 (14.0) 
Samples for Outcomes Assessment  
647 
 
(Sept 2007 to February 2011) 
240 
•Not engaged in the program 
(i.e., had two or less contacts 
with the program) 
•Enrolled in program after 
October, 2010  
407 
Intent to treat 
100 
Program non-completers 
307 
program completers 
Smoking cessation: 7-day point-prevalence of abstinence at end of treatment (i.e., anytime 
between 8 weeks to 26 weeks) verified by expired CO levels 
Tobacco Dependence Clinic Butt Out Group 
76 
 
(July 2010-April 2011) 
2 
• 2 Not engaged in 
the program (i.e., 
had two or less 
contacts with the 
program) 
74 
Intent to treat 
10 
Program non-completers 
64 
program completers 
Program Completion 
0
20
40
60
80
100
Completed program?
75%
25%
Yes
No
0
20
40
60
80
100
Completed program?
86.5
13.5
Yes
No
TDC (N = 307/407) Butt Out Group (N = 64/74) 
TDC Smoking Cessation Outcomes at end-of-treatment* 
* End-of-treatment (i.e., anytime between 8 weeks to 26 weeks) verified by expired CO levels 
Butt Out group Smoking Cessation* Outcomes  
at end-of-treatment  
0 
20 
40 
60 
80 
100 
Intent-to-treat                      
(N = 74) 
Program completers           
(n = 64) 
27.0 31.3 
73.0 
68.7 
Quit  
Not quit 
*End-of-treatment (i.e., anytime between 8 weeks to 26 weeks) verified by expired CO levels 
P
e
rc
e
n
t 
%
 

Conclusions 
 
• With intensive tobacco dependence treatment 
provided within Mental Health and Addictions services, 
individuals with a history of substance use disorders and 
mental illness are able to achieve smoking abstinence. 
 
• Tobacco treatment should include best practices using 
behavioural counseling combined with 
pharmacotherapy.  
 
• Treatment durations beyond 12-weeks should be 
considered to maximize effectiveness of programs 
 
 
 
Current and Future Projects 
• Current projects: 
o Smoking Cessation Program among Individuals with Mental 
Illness (PARTICIPATION STATION- a peer led mental health 
support program) 
o Understanding the behavioural effects of secondhand tobacco 
smoke exposure among nonsmokers 
o Examining sex and gender differences in tobacco dependence 
outcomes among smokers with co-occurring substance use and 
psychiatric disorders 
 
 
• Future Projects: 
o Developing a tailored tobacco dependence treatment 
program for individuals with Chronic Mental Illnesses 
o Examining the effect of different tobacco products on nicotine 
dependence, symptoms severity, and smoking cessation 
among individuals with mental illnesses. 
Questions?? 
 
